pegcetacoplan

💊Medication

Generic name

Pegcetacoplan

Brand names

Syfovre

Drug class

Complement Inhibitor, Complement Inhibitors

Route

Intravitreal

Type

Human Prescription Drug

Manufacturer

Apellis Pharmaceuticals, Inc.

Indications: 1 INDICATIONS AND USAGE SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). SYFOVRE is a complement inhibitor indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). ( 1 ) (per FDA label)

• APPROVED_FOR_MARKETING
  C3G/Primary IC-MPGN EAPApellis Pharmaceuticals, Inc. · NCT04729062
• PHASE3COMPLETED
  An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDApellis Pharmaceuticals, Inc. · NCT04770545
• PHASE2COMPLETED
  A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNHApellis Pharmaceuticals, Inc. · NCT03593200
• PHASE1COMPLETED
  Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.Apellis Pharmaceuticals, Inc. · NCT02588833
• PHASE2RECRUITING
  A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular DegeneratioApellis Pharmaceuticals, Inc. · NCT07215390
• NOT_YET_RECRUITING
  Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).University of Utah · NCT07582042

via ClinicalTrials.gov